Last reviewed · How we verify
Utidelone plus Metronomic Capecitabine
Utidelone is a chemotherapy medication that works by interfering with DNA replication, while metronomic capecitabine is a prodrug that is converted into 5-fluorouracil, which inhibits thymidylate synthase.
Utidelone is a chemotherapy medication that works by interfering with DNA replication, while metronomic capecitabine is a prodrug that is converted into 5-fluorouracil, which inhibits thymidylate synthase. Used for Metastatic breast cancer.
At a glance
| Generic name | Utidelone plus Metronomic Capecitabine |
|---|---|
| Sponsor | Sun Yat-sen University |
| Drug class | Chemotherapy |
| Target | Topoisomerase II, Thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Utidelone is a topoisomerase inhibitor that binds to the topoisomerase II-DNA complex, preventing DNA replication. Metronomic capecitabine, on the other hand, is a prodrug that is converted into 5-fluorouracil, which is then converted into 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP), a potent inhibitor of thymidylate synthase. This inhibition leads to the depletion of thymidine, a nucleotide required for DNA synthesis, thereby inhibiting cancer cell growth.
Approved indications
- Metastatic breast cancer
Common side effects
- Neutropenia
- Diarrhea
- Fatigue
- Nausea
- Vomiting
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Utidelone plus Metronomic Capecitabine CI brief — competitive landscape report
- Utidelone plus Metronomic Capecitabine updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI